N/A N=38 The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance
Oxidative Stress
Primary: 5-km Running Time — 20.2; 20.4; 20.0; 20.1 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=52 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes in the At Risk Primed Group. — 1.94; 6.16; 2.44; 3.66 μg/mL
Phase 2 N=10 Development of NIC5-15 in the Treatment of Alzheimer's Disease
Alzheimer Disease · Dementia
Primary: Safety Assessments: Number of Participants With Adverse Events — 07; 02 Participants
N/A N=20 Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Low Grade Gliomas
Primary: Number of Participants With Late Effects > 3 Months Post RT — 20 Participants
Phase 4 N=19 Pharmacogenomics of Antiplatelet Response - I
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
N/A N=10 Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy
Tobacco Use Disorder
Primary: Number of Days of Inhaler Use — 26.4 days
Phase 1 N=17 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Melanoma · Sarcoma · Gastrointestinal Stromal Tumor (GIST)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 13; 4; 3; 2 participants
Phase 2 N=18 Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
Nicotine Dependence
Primary: 4-week, Continuous Tobacco Abstinence at the End of the 6-week, Double Blind, Treatment Phase — 0; 0 Participants
N/A N=46 Progesterone & Postpartum Relapse to Smoking
Tobacco Use Cessation · Tobacco Use Disorder
Primary: Number of Participants Who Relapsed by Week 4 Postpartum — 6; 7 participants
Phase 4 N=33 Pharmacogenomics of Antiplatelet Response - II (PARes-II)
Atherothrombosis
Primary: Changes in Platelet Transcriptome — 77.1 FPKM difference for HBG1 Gene
Phase 2 N=100 Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
Epilepsy
Primary: Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years — 0.825 ug/mL
N/A N=158 Progel Vascular Sealant
Aortic Valve Stenosis · Aneurysm of Ascending Aorta · Aortic Valve Disorder
Primary: Time to Achieve Hemostasis at the Aortic Anastomotic Suture Line From the Time Surgical Clamps Are Released to Cessation of Leakage at the Treated Anastomotic Site With…
Phase 4 N=100 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)
Ulcerative Colitis
Primary: Percentage of Participants Who Prefer Prefilled Syringe, Smartject™ Device, or Are Undecided (Day of Injections) — 20.9; 76.9; 2.2 Percentage of Participants
Phase 2 N=59 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
Ductal Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Number of Participants With Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) — 22 Participants — p=<0.001